On April 7, Judge David Joseph of the U.S. District Court for the Western District of Louisiana granted the Department of Justice’s motion to stay Louisiana’s case attempting to restrict access to the medication mifepristone while the Food and Drug Administration conducts its own review of the medication based on discredited antiabortion propaganda.
The court denied Louisiana’s motion for a preliminary injunction to bar patients nationwide from obtaining mifepristone by mail via telehealth or at pharmacies, instead requiring them to pick up the medication in person from a medical provider.
As a result of Joseph’s ruling, mifepristone access will not change across the country.
“Putting this baseless case on hold is certainly a better outcome than what Louisiana asked for: severe and immediate restrictions on mifepristone that would upend abortion and miscarriage care across the country,” said Julia Kaye, senior staff attorney for the Reproductive Freedom Project of the American Civil Liberties Union (ACLU). “But it is small comfort that the Trump administration now holds the baton in this ongoing attack on medication abortion when we can see the administration teeing up the same harmful restrictions that abortion opponents are trying to win in court.
Many observers believe that the Trump administration wants to delay restrictions on mifepristone until after the November elections because early abortion with pills is broadly popular across the political spectrum.